EP1616861A2 - A process for the preparation of keto compounds - Google Patents

A process for the preparation of keto compounds Download PDF

Info

Publication number
EP1616861A2
EP1616861A2 EP05011646A EP05011646A EP1616861A2 EP 1616861 A2 EP1616861 A2 EP 1616861A2 EP 05011646 A EP05011646 A EP 05011646A EP 05011646 A EP05011646 A EP 05011646A EP 1616861 A2 EP1616861 A2 EP 1616861A2
Authority
EP
European Patent Office
Prior art keywords
formula
compound
ranges
sulfuric acid
alkanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05011646A
Other languages
German (de)
French (fr)
Other versions
EP1616861A3 (en
Inventor
Graziano Castaldi
Giuseppe Barreca
Antonio Tarquini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dipharma Francis SRL
Original Assignee
Dipharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20041191 external-priority patent/ITMI20041191A1/en
Priority claimed from ITMI20041397 external-priority patent/ITMI20041397A1/en
Application filed by Dipharma SpA filed Critical Dipharma SpA
Publication of EP1616861A2 publication Critical patent/EP1616861A2/en
Publication of EP1616861A3 publication Critical patent/EP1616861A3/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the alkyne of formula ( II ) is reacted in the form of a solution in a C 1 -C 4 alkanol, as defined above, in a concentration approx. from 10 to 30%, preferably from 15 to 25% weight/volume.
  • the reaction is carried out contacting the alkanol solution of the alkyne of formula ( II ) with the sulfuric acid aqueous solution in molar amounts of sulfuric acid to alkyne of formula ( II ) ranging approx. from 0.8 to 1.2, preferably from 0.9 to 1.1.
  • the resulting solution is added with HgO in molar amounts to the alkyne of formula ( II ) ranging approx. from 0.01 to 0.05, preferably from 0.02 to 0.04.
  • the reaction is carried out at a temperature ranging approx. from 20 to 60°C, preferably from 30 to 50°C.

Abstract

A process for the preparation of 4-[1-oxo-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid, useful as an intermediate in the preparation of fexofenadine.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a novel process for the preparation of 4-[1-oxo-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid and its use in the preparation of fexofenadine.
  • TECHNOLOGICAL BACKGROUND
  • A number of processes for the preparation of fexofenadine are known, for example those disclosed in WO 93/21156, WO 97/22344 and WO 97/23213, characterized by a high number of steps. None of the known processes involves a convergent approach, but the construction of the molecule through stepwise introduction of the different functionalities starting from α,α-dimethylbenzeneacetic acid. An alternative route is described by Kawai S. et al. in J. Org. Chem. 1994, 59, 2620-2622, but it has some disadvantages which prevent its industrial application. A key step in said synthetic route is, in fact, the hydration of the alkyne bond in the carboxymethyl ester of formula (A) to give the respective keto derivative of formula (B).
    Figure imgb0001
  • This is however accompanied by formation of by-products, which are difficult to remove from the final product. The paper by Kawai S. et al. describes in fact the subsequent purification of the ketone of formula (B) by silica gel chromatography. It is well-known that this technique is hardly suitable for the production of large amounts of the product, so that this process is not industrially applicable. The problem of the formation of by-products was solved by EP 1260505, in which the hydration is carried out using a catalyst based on platinum, palladium or ruthenium, optionally in the presence of ligands. The very high cost of these catalysts, however, negatively affects the final costs. Therefore, there still is the problem of hydrating the alkyne bond to obtain the corresponding keto compound, avoiding the formation of hardly removable by-products as well as the increase in industrial production costs.
  • SUMMARY OF THE INVENTION
  • It has now surprisingly been found that the reaction between the alkyne of formula (A), in the form of the free carboxylic acid, and a solution of HgO in H2SO4 provides the respective keto derivative in industrial yields, without need for expensive catalysts as well as complex, time-consuming purification operations.
  • DETAILED DISCLOSURE OF THE INVENTION
  • The object of the invention is a process for the preparation of a compound of formula (I)
    Figure imgb0002
    comprising the reaction of a compound of formula (II)
    Figure imgb0003
    with a sulfuric acid aqueous solution, in the presence of mercury(II) oxide, in a C1-C4 alkanol.
  • A C1-C4 alkanol, in which the alkyl moiety can be straight or branched, is preferably methanol or ethanol, in particular methanol.
  • The alkyne of formula (II) is reacted in the form of a solution in a C1-C4 alkanol, as defined above, in a concentration approx. from 10 to 30%, preferably from 15 to 25% weight/volume.
  • The sulfuric acid aqueous solution is typically a solution approx. from 30 to 50%, preferably from 35 to 45% weight/volume.
  • The reaction is carried out contacting the alkanol solution of the alkyne of formula (II) with the sulfuric acid aqueous solution in molar amounts of sulfuric acid to alkyne of formula (II) ranging approx. from 0.8 to 1.2, preferably from 0.9 to 1.1. The resulting solution is added with HgO in molar amounts to the alkyne of formula (II) ranging approx. from 0.01 to 0.05, preferably from 0.02 to 0.04. The reaction is carried out at a temperature ranging approx. from 20 to 60°C, preferably from 30 to 50°C.
  • After completion of the reaction, the reaction mixture is alkalinised with a sodium hydroxide methanolic solution, the resulting sodium salt of the ketone of formula (I) is transformed into the corresponding free acid by treatment with a mineral acid, such as hydrochloric, sulfuric or phosphoric acid, or an organic acid, for example acetic, methanesulfonic or oxalic acid.
  • The resulting ketone of formula (I): 4-{[4-(4-hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl}-α,α-dimethylbenzeneacetic acid, has crystalline structure having X-ray diffraction spectrum (X-ray powder diffraction, XRPD) substantially as reported in the Figure, the more intense diffraction peaks being observed at 10.05; 12.03; 15.33; 15.78; 17.34; 17.64; 20.13 and 23.67 in 2θ, and this is a further object of the invention. The XRPD spectrum was recorded with an APD 2000 automatic diffractometer θ/θ for powders and liquids (available from Ital-Structures), under the following operative conditions: CuKα radiation (λ = 1.5418 A), scanning with angular pass of 0.03° for a time of 1 sec".
  • The comparative data reported in the following table show the advantages provided by the process of the present invention compared with that described by Kawai S. et al. Table
    Starting alkyne Starting mols Keto compound Mols of keto compound % Yield
    Compound (A) 1.18 Compound (B) 0.885 75
    Compound (II) 1.18 Compound (I) 1.062* 90*
    0.968** 82**
    (*): values obtained by titration of the final reaction mixture.
    (**): values concerning the isolated product.
  • Since the formed by-products are difficult to remove, when the reaction is carried out according to Kawai S. et al., the purification of the ketone of formula (B) is carried out by silica gel chromatography (1:2 → 3:1 ethyl acetate - hexane, then 15:1 CH2-Cl2 - methanol, v/v), as described in the same paper. On the other hand, the keto compound of formula (I), after work up, is separated by simple precipitation. Moreover, the amount of HgO used according to the process of the invention is about 1/10 that used by Kawai S. et al., thereby reducing the environmental impact.
  • The keto compound of formula (I) can be subsequently reduced to obtain fexofenadine of formula (III)
    Figure imgb0004

    by means of known procedures, for example, by a process comprising the reduction with a reducing agent, such as sodium borohydride, potassium borohydride, sodium cyanoborohydride or tetramethylammonium borohydride, in a suitable alkanol, such as methanol, ethanol, isopropanol, n-butanol or mixtures thereof with water, at a temperature ranging from about 0°C to the reflux temperature of the reaction mixture. If desired, fexofenadine can then be converted into a salt, for example the hydrochloride, according to known methods.
  • Therefore, the present invention also relates to a process for the preparation of fexofenadine, or a pharmaceutically acceptable salt thereof, comprising the reduction of a keto compound of formula (I)
    Figure imgb0005

    and, if desired, the conversion into a salt thereof, such as the hydrochloride, characterized in that the compound of formula (I) is obtained by reaction of a compound of formula (II)
    Figure imgb0006

    with a sulfuric acid aqueous solution, in the presence of mercury(II) oxide, in a C1-C4 alkanol, as herein described.
  • The following example illustrates the invention.
  • Example: Synthesis of 4-{[4-(4-hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl}-α,α -dimethylbenzeneacetic acid; (I)
  • A four-necked three litres flask, equipped with stirrer, thermometer, condenser and kept under nitrogen, is loaded with 353 g of 4-{[4-(4-hydroxydiphenylmethyl)-1-piperidinyl]-1-butynyl}-α,α-dimethylbenzeneacetic acid and 1790 ml of methanol. A solution of 72 g of 96% w/w sulfuric acid in 185 g of water is prepared in a 500 ml flask and added with 4.1 g of mercury(II) oxide under stirring. The resulting suspension of 4-{[4-(4-hydroxydiphenylmethyl)-1-piperidinyl]-1-butynyl}-α,α-dimethylbenzeneacetic acid in methanol is added with the mercury sulfate aqueous solution prepared above. The resulting solution is heated at about 40°C under stirring, keeping this temperature until completion of the reaction. (The yield being now above 90%). A solution of sodium hydroxide scales (86 g) in 430 ml of methanol is prepared and added with the reaction mixture at room temperature: temperature spontaneously raises, to obtain a suspension. The mixture is refluxed and 66 g of glacial acetic acid are dropped therein. After adding approx. 30% of the acid, crystallization is started with the previously obtained pure keto compound (I), and the addition is completed. After that, the mixture is refluxed for about 15-20 minutes, then cooled in approx. 2 hours at 25-30°. The mixture is left at this temperature for approx. an hour and the solid is filtered and washed with methanol (2x100 ml). The resulting solid is further purified from the inorganic salts by hot trituration in 950 ml of water and filtration at 60-65°C. After washing with 100 ml x 2 of water and washing with 100 ml x 2 of methanol, the product is dried. 281 g of compound (I) in the crystalline form, having an XRPD spectrum substantially as reported in the Figure, are obtained; (purity above 99.5%; yield 82%).

Claims (13)

  1. A process for the preparation of a compound of formula (I)
    Figure imgb0007
    comprising the reaction of a compound of formula (II)
    Figure imgb0008
    with a sulfuric acid aqueous solution, in the presence of mercury(II) oxide, in a C1-C4 alkanol.
  2. A process as claimed in claim 1, wherein the alkanol is methanol or ethanol.
  3. A process as claimed in claims 1 or 2, wherein the concentration of the compound of formula (II) in the alkanol ranges from 10 to 30% weight/volume.
  4. A process as claimed in claims 1 or 3, wherein the concentration of the sulfuric acid aqueous solution ranges from 30 to 50% weight/volume.
  5. A process as claimed in claims 1 or 4, wherein the molar amount of sulfuric acid to compound of formula (II) ranges from 0.8 to 1.2.
  6. A process as claimed in claim 5, wherein the molar amount of sulfuric acid to compound of formula (II) ranges from 0.9 to 1.1.
  7. A process as claimed in claims 1 or 6, wherein the molar amount of mercury(II) oxide to compound of formula (II) ranges from 0.01 to 0.05.
  8. A process as claimed in claim 7, wherein the molar amount of mercury(II) oxide to compound of formula (II) ranges from 0.02 to 0.04.
  9. 4-{[4-(4-Hydroxydiphenylmethyl)-1-piperidinyl]-1-oxobutyl}-α,α-dimethylbenzeneacetic acid in the crystalline form.
  10. A process for the preparation of fexofenadine, or a pharmaceutically acceptable salt thereof, comprising the reduction of a keto compound of formula (I)
    Figure imgb0009
    and, if desired, the conversion into a salt thereof, characterized in that the compound of formula (I) is obtained by reaction between a compound of formula (II)
    Figure imgb0010
    and a sulfuric acid aqueous solution, in the presence of mercury(II) oxide, in a C1-C4 alkanol, as claimed in each of claims 1 to 8.
  11. A process as claimed in claim 10, wherein the fexofenadine salt is the hydrochloride.
  12. A crystalline form of the acid of claim 9, having an XRPD spectrum substantially as reported in the Figure.
  13. A crystalline form as claimed in claim 12, having an XRPD spectrum in which the more intense diffraction peaks are observed at 10.05; 12.03; 15.33; 15.78; 17.34; 17.64; 20.13 and 23. 67 in 20.
EP05011646A 2004-06-15 2005-05-31 A process for the preparation of keto compounds Withdrawn EP1616861A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20041191 ITMI20041191A1 (en) 2004-06-15 2004-06-15 PROCEDURE FOR THE PREPARATION OF KETONIC COMPOUNDS
ITMI20041397 ITMI20041397A1 (en) 2004-07-13 2004-07-13 PROCEDURE FOR THE PREPARATION OF KETONIC COMPOUNDS

Publications (2)

Publication Number Publication Date
EP1616861A2 true EP1616861A2 (en) 2006-01-18
EP1616861A3 EP1616861A3 (en) 2006-02-08

Family

ID=35461376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05011646A Withdrawn EP1616861A3 (en) 2004-06-15 2005-05-31 A process for the preparation of keto compounds

Country Status (4)

Country Link
US (1) US20050277775A1 (en)
EP (1) EP1616861A3 (en)
JP (1) JP2006001931A (en)
CA (1) CA2510001A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992615A1 (en) 2007-05-16 2008-11-19 Dipharma Francis S.r.l. A process for the preparation of keto compounds
ITMI20090311A1 (en) * 2009-03-04 2010-09-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF KETONIC INTERMEDIATES
ITMI20132023A1 (en) * 2013-12-05 2015-06-06 Dipharma Francis Srl "METHOD OF PURIFICATION OF A KETONIC COMPOUND"

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532356A (en) * 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド Polymorph XVI of fexofenadine hydrochloride
ITMI20131652A1 (en) 2013-10-07 2015-04-08 Dipharma Francis Srl PROCEDURE FOR THE PURIFICATION OF DERIVATIVES OF 2-PHENYL-2-METHYL-PROPANOIC ACID

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5654433A (en) * 1993-01-26 1997-08-05 Merrell Pharmaceuticals Inc. Process for piperidine derivatives
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
EP1260505A1 (en) * 2001-05-17 2002-11-27 Dinamite Dipharma S.p.A. A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid
US20030166682A1 (en) * 2000-07-28 2003-09-04 Milla Federico Junquera Processes for the production of fexofenadine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5654433A (en) * 1993-01-26 1997-08-05 Merrell Pharmaceuticals Inc. Process for piperidine derivatives
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
US20030166682A1 (en) * 2000-07-28 2003-09-04 Milla Federico Junquera Processes for the production of fexofenadine
EP1260505A1 (en) * 2001-05-17 2002-11-27 Dinamite Dipharma S.p.A. A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAI S H ET AL: "A FACILE SYNTHESIS OF AN OXIDANT PRODUCT OF TERFENADINE" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 59, 1994, pages 2620-2622, XP002064406 ISSN: 0022-3263 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992615A1 (en) 2007-05-16 2008-11-19 Dipharma Francis S.r.l. A process for the preparation of keto compounds
US8236961B2 (en) 2007-05-16 2012-08-07 Dipharma Francis S.R.L. Process for the preparation of keto compounds
ITMI20090311A1 (en) * 2009-03-04 2010-09-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF KETONIC INTERMEDIATES
ITMI20132023A1 (en) * 2013-12-05 2015-06-06 Dipharma Francis Srl "METHOD OF PURIFICATION OF A KETONIC COMPOUND"

Also Published As

Publication number Publication date
US20050277775A1 (en) 2005-12-15
EP1616861A3 (en) 2006-02-08
JP2006001931A (en) 2006-01-05
CA2510001A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
JP5421265B2 (en) Preparation of disubstituted piperidines and intermediates
RU2163597C2 (en) Method of synthesis of 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)- -4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridine dicarbo-xylate and benzenesulfoacid salt (amlodipine bezylate)
AP708A (en) Processes and intermediates for preparing 1-Benzyl-4-((5,6-Dimethoxy-1-Incanon)-2-Y1) Methylpiperidine.
EP1616861A2 (en) A process for the preparation of keto compounds
EP1386607B1 (en) Process for the preparation of Donepezil
EP1992615B1 (en) A process for the preparation of keto compounds
US6583285B1 (en) Process for preparing zolpidem
WO2005003092A1 (en) Preparation of intermediates for acetyl cholinesterase inhibitors
CA2445766A1 (en) Improved process for preparing zolpidem
JP2009051812A6 (en) Production of keto compounds
US20100228034A1 (en) Process for the preparation of keto intermediates
CA2217171C (en) New process for preparing (-)-trans-n-p-fluorobenzoylmethyl-4-(p-fluorophenyl)-3-¢¢3,4-(methylenedioxy)phenoxy!methyl!-piperidine
KR100288404B1 (en) 2-Benzothiazolyl 4-amino-5-chloro-2-methoxythiobenzoate And Process For Preparing Cisapride Employing The Same
EP3365327B1 (en) Process for the preparation of fexofenadine and of intermediates used therein
KR100374405B1 (en) A new process for amlodipine besylate
US7045630B2 (en) Method for preparing 4-amino-4-phenylpiperidines
KR100808281B1 (en) Method for the preparation of lercanidipine and acid addition salt thereof
JPS62273950A (en) 4-alkoxy-3-pyrroline-2-one-1-yl-acetic acid amide, manufacture and use
KR20050122481A (en) Novel intermediate compound for amlodipine besylate and preparation process of amlodipine besylate using thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20060724

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20060929

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIPHARMA FRANCIS S.R.L.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110114